tiprankstipranks
Advertisement
Advertisement
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
PremiumThe FlyFulcrum Therapeutics move lower ‘overdone,’ says Stifel
1M ago
Truist remain buyers of Fulcrum Therapeutics shares on weakness
Premium
The Fly
Truist remain buyers of Fulcrum Therapeutics shares on weakness
1M ago
Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
Premium
The Fly
Fulcrum Therapeutics announces results from Phase 1b PIONEER trial of pociredir
1M ago
JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
PremiumThe FlyJPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
1M ago
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
Premium
Ratings
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
2M ago
Fulcrum Therapeutics updates strategy on lead sickle cell therapy
Premium
Company Announcements
Fulcrum Therapeutics updates strategy on lead sickle cell therapy
2M ago
Fulcrum Therapeutics price target raised to $7 from $6 at BofA
PremiumThe FlyFulcrum Therapeutics price target raised to $7 from $6 at BofA
4M ago
Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
Premium
Ratings
Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
4M ago
Fulcrum Therapeutics announces $150M offering of common stock
Premium
The Fly
Fulcrum Therapeutics announces $150M offering of common stock
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100